Text Size: A- A+ Facebook Twitter LinkedIn YouTube

Breaking News

Pledge the Gift of Life

Each year, the lives of thousands of people across the country are saved because someone made the choice to become an organ donor. In April, Allegheny Health Network is honored to celebrate National Donate Life Month and pay tribute to all of those who have bestowed the precious gift of life to another through organ donation. Visit AHNdonate.org to learn more and register to be an organ donor.



Format: 04/23/2014
Format: 04/23/2014


Ventripoint VMS Heart Analysis System Installed at Allegheny General Hospital

Monday, May 7th, 2012

SEATTLE, WASHINGTON: VentriPoint Diagnostics Ltd. (TSXV: VPT; OTCQX: VPTDF) has installed its latest version of the VMS™ heart analysis system at Allegheny General Hospital in Pittsburgh to support its clinical trials program and for other research purposes. The first Pulmonary Arterial Hypertension (PAH) patient has completed the MRI and VMS™ scans.
The VMS™ heart analysis system works with all existing 2D cardiac ultrasound machines to obtain 3D functional information in 15 minutes. The heart information is identical to the same information obtained in an MRI, which takes over an hour. This revolutionary approach has been publish in major medical journals in 2010 and 2011 and is now in routine clinical use in Europe and Canada.  
“This technology has the potential to transform the assessment of patients with PAH. It combines the speed and ease of echocardiography with 3 dimensional quantitative assessment of the heart’s right ventricular structure and function, a capability previously available only with MRI", said Dr. Amresh Raina, Heart Failure/Transplant & Pulmonary Hypertension, Allegheny General Hospital and Assistant Professor of Medicine, Temple University School of Medicine.
PAH, the most serious form of the five recognized groups of pulmonary hypertension, is a devastating disease with an average patient lifespan of less than 3 years after diagnosis if untreated. It affects individuals from infancy to the elderly. It is widely known that PAH patients treated early after detection have better results than patients that start later. As it stands, the majority of patients with PAH continue to be diagnosed too late for treatment to be fully effective. PAH can occur for no known reason but will typically occur in association with many common conditions such as chronic liver disease and liver cirrhosis; connective tissue disorders such as scleroderma or systemic lupus erythematosus (lupus); congenital heart disease (even if repaired) and HIV. With increasing availability of effective therapies, and evidence-based treatment guidelines recommending starting treatment early, tests enabling detection as early as possible should prove invaluable.
“Allegheny is a major centre for treating pulmonary hypertension and so with our success in validating the Pulmonary Arterial Hypertension application, said Dr. George Adams, CEO of VentriPoint. “We are expecting to have all the data we require for submission to the FDA in Q3 of this year.
The VMS™ is for investigational use only in the United States and is approved for sale and clinical use in Canada and Europe.
About VentriPoint Diagnostics Ltd.
VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. Management believes the VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease is the first application in a suite of applications for all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure, which management believes has a multibillion-dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of VentriPoint’s VMS™ heart analysis system and VentriPoint is pursuing the US-FDA approval through the 510(k) process.


FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint’s expectations, should be considered forward-looking statements. Such statements are based on management’s exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. These forward-looking statements are made as of the date of this press release and, other than as required by applicable securities laws, the Corporation does not assume any obligation to update or revise them to reflect new events or circumstances. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release
For more information, contact:
West Penn Allegheny Health System
Tell us who you are:

What areas do you use on our website?*
(select more than one if it applies)

Did you find what you were looking for?

Would you refer others to our website?

Can we contact you for future questions?

CAPTCHA math question:* 8 + 9 =

Thank you for completing the West Penn Allegheny Health System website survey.
We value your feedback and comments.